Targeted accumulation of selective anticancer depsipeptides by reconstructing the precursor supply in the neoantimycin biosynthetic pathway

Abstract

Background

Neoantimycins are a group of 15-membered ring depsipeptides isolated from Streptomycetes with a broad-spectrum of anticancer activities. Neoantimycin biosynthesis is directed by the hybrid multimodular megaenzymes of non-ribosomal peptide synthetase and polyketide synthase. We previously discovered a new neoantimycin analogue unantimycin B, which was demonstrated to have selective anticancer activities and was produced from the neoantimycin biosynthetic pathway with a starter unit of 3-hydroxybenzoate, instead of the 3-formamidosalicylate unit that is common for neoantimycins. However, the low fermentation titre and tough isolation procedure have hindered in-depth pharmacological investigation of unantimycin B as an anticancer agent.

Results

In this work, we genetically constructed two unantimycin B producer strains and inhibited neoantimycins production by removing natO and natJ-L genes essential for 3-formamidosalicylate biosynthesis, therefore facilitating chromatographic separation of unantimycin B from the complex fermentation extract. Based on the ΔnatO mutant, we improved unantimycin B production twofold, reaching approximately 12.8 mg/L, by feeding 3-hydroxybenzoate during fermentation. Furthermore, the production was improved more than sixfold, reaching approximately 40.0 mg/L, in the ΔnatO strain introduced with a chorismatase gene highly expressed under a strong promoter for endogenously over-producing 3-hydroxybenzoate.

Conclusion

This work provides a case of targeting accumulation and significant production improvement of medicinally interesting natural products via genetic manipulation of precursor biosynthesis in Streptomycetes, the talented producers of pharmaceutical molecules.

Keywords

Anticancer / Depsipeptides / Natural product biosynthesis / 3-Hydroxybenzoate / 3-Formamidosalicylate / Chorismic acid

References

[1] Fox B P, Wang H (2008) Expression of streptomyces subtilisin inhibitor (SSI) proteins in Bacillus and Streptomyces sp. Patent WO2009096916, Publication: 29 Jan 2008

[2] Fries A, Mazzaferro LS, Grüning B, Bisel P, Stibal K, Buchholz PCF, Pleiss J, Sprenger GA, Müller M. Alteration of the route to menaquinone towards isochorismate-derived metabolites. ChemBioChem, 2019, 20(13): 1672-1677.

[3] Gregory MA, Till R, Smith MC. Integration site for Streptomyces phage phiBT1 and development of site-specific integrating vectors. J Bacteriol, 2003, 185(17): 5320-5323.

[4] Izumikawa M, Ueda JY, Chijiwa S, Takagi M, Shin-ya K. Novel GRP78 molecular chaperone expression down-regulators JBIR-04 and -05 isolated from Streptomycesviolaceoniger. J Antibiot (tokyo), 2007, 60(10): 640-644.

[5] Li X, Zvanych R, Vanner SA, Wang W, Magarvey NA. Chemical variation from the neoantimycin depsipeptide assembly line. Bioorg Med Chem Lett, 2013, 23(18): 5123-5127.

[6] Lim CL, Nogawa T, Okano A, Futamura Y, Kawatani M, Takahashi S, Ibrahim D, Osada H. Unantimycin A, a new neoantimycin analog isolated from a microbial metabolite fraction library. J Antibiot (tokyo), 2016, 69(6): 456-458.

[7] Lin X, Zhou Y, Liu L, Zhu H, Chen Y, Wang S, Sun F, Chai L, Liu B, Xu S, Lin HW. Compound discovery and structure-activity relationship study of neoantimycins against drug-resistant cancer cells. Front Chem, 2019, 7: 481.

[8] Liu J, Zhu X, Seipke RF, Zhang W. Biosynthesis of antimycins with a reconstituted 3-formamidosalicylate pharmacophore in Escherichiacoli. ACS Synth Biol, 2015, 4(5): 559-565.

[9] Liu J, Zhu X, Kim SJ, Zhang W. Antimycin-type depsipeptides: discovery, biosynthesis, chemical synthesis, and bioactivities. Nat Prod Rep, 2016, 33(10): 1146-1165.

[10] Liu R, Deng Z, Liu T. Streptomyces species: ideal chassis for natural product discovery and overproduction. Metab Eng, 2018, 50: 74-84.

[11] Liu L, Zhu H, Wu W, Shen Y, Lin X, Wu Y, Liu L, Tang J, Zhou Y, Sun F, Lin HW. Neoantimycin F, a streptomyces-derived natural product induces mitochondria-related apoptotic death in human non-small cell lung cancer cells. Front Pharmacol, 2019, 10: 1042.

[12] Sandy M, Rui Z, Gallagher J, Zhang W. Enzymatic synthesis of dilactone scaffold of antimycins. ACS Chem Biol, 2012, 7(12): 1956-1961.

[13] Schoenian I, Paetz C, Dickschat JS, Aigle B, Leblond P, Spiteller D. An unprecedented 1,2-shift in the biosynthesis of the 3-aminosalicylate moiety of antimycins. ChemBioChem, 2012, 13(6): 769-773.

[14] Shen Y, Sun F, Zhang L, Cheng Y, Zhu H, Wang SP, Jiao WH, Leadlay PF, Zhou Y, Lin HW. Biosynthesis of depsipeptides with a 3-hydroxybenzoate moiety and selective anticancer activities involves a chorismatase. J Biol Chem, 2020, 295(16): 5509-5518.

[15] Skyrud W, Liu J, Thankachan D, Cabrera M, Seipke RF, Zhang W. Biosynthesis of the 15-membered ring depsipeptide neoantimycin. ACS Chem Biol, 2018, 13(5): 1398-1406.

[16] Sprenger GA. From scratch to value: engineering Escherichiacoli wild type cells to the production of L-phenylalanine and other fine chemicals derived from chorismate. Appl Microbiol Biotechnol, 2007, 75(4): 739-749.

[17] Van der Heul HU, Bilyk BL, McDowall KJ, Seipke RF, Van Wezel GP. Regulation of antibiotic production in Actinobacteria: new perspectives from the post-genomic era. Nat Prod Rep, 2018, 35(6): 575-604.

[18] Wang W, Li X, Wang J, Xiang S, Feng X, Yang K. An engineered strong promoter for streptomycetes. Appl Environ Microbiol, 2013, 79(14): 4484-4492.

[19] Wilkinson CJ, Hughes-Thomas ZA, Martin CJ, Böhm I, Mironenko T, Deacon M, Wheatcroft M, Wirtz G, Staunton J, Leadlay PF. Increasing the efficiency of heterologous promoters in actinomycetes. J Mol Microbiol Biotechnol, 2002, 4(4): 417-426.

[20] Yan Y, Zhang L, Ito T, Qu X, Asakawa Y, Awakawa T, Abe I, Liu W. Biosynthetic pathway for high structural diversity of a common dilactone core in antimycin production. Org Lett, 2012, 14(16): 4142-4145.

[21] Zhou Y, Lin X, Williams SR, Liu L, Shen Y, Wang SP, Sun F, Xu S, Deng H, Leadlay PF, Lin HW. Directed accumulation of anticancer depsipeptides by characterization of neoantimycins biosynthetic pathway and an NADPH-dependent reductase. ACS Chem Biol, 2018, 13(8): 2153-2160.

Funding

National Natural Science Foundation of China(31670096)